BG62474B1 - Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори - Google Patents

Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори Download PDF

Info

Publication number
BG62474B1
BG62474B1 BG99499A BG9949995A BG62474B1 BG 62474 B1 BG62474 B1 BG 62474B1 BG 99499 A BG99499 A BG 99499A BG 9949995 A BG9949995 A BG 9949995A BG 62474 B1 BG62474 B1 BG 62474B1
Authority
BG
Bulgaria
Prior art keywords
day
cineol
mentan
therapy
use according
Prior art date
Application number
BG99499A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG99499A (bg
Inventor
Uwe R. Juergens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4319554A external-priority patent/DE4319554C2/de
Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de
Application filed filed Critical
Publication of BG99499A publication Critical patent/BG99499A/bg
Publication of BG62474B1 publication Critical patent/BG62474B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG99499A 1993-06-13 1995-03-13 Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори BG62474B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4319554A DE4319554C2 (de) 1993-06-13 1993-06-13 Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
DE19934319556 DE4319556C2 (de) 1993-06-13 1993-06-13 Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (de) 1993-06-13 1994-06-11 Verwendung von terpenverbindungen zur verminderten freisetzung von arachidonsäure und entzündungsmediatoren

Publications (2)

Publication Number Publication Date
BG99499A BG99499A (bg) 1995-12-29
BG62474B1 true BG62474B1 (bg) 1999-12-30

Family

ID=25926728

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99499A BG62474B1 (bg) 1993-06-13 1995-03-13 Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори

Country Status (19)

Country Link
US (1) US5889049A (pt)
EP (1) EP0654994B1 (pt)
JP (1) JPH08500612A (pt)
AT (1) ATE173622T1 (pt)
AU (1) AU680663B2 (pt)
BG (1) BG62474B1 (pt)
BR (1) BR9405404A (pt)
CA (1) CA2140660A1 (pt)
CZ (1) CZ285025B6 (pt)
DE (1) DE59407336D1 (pt)
DK (1) DK0654994T3 (pt)
ES (1) ES2126123T3 (pt)
HU (1) HUT69684A (pt)
NO (1) NO313814B1 (pt)
PL (1) PL308539A1 (pt)
RO (1) RO111989B1 (pt)
RU (1) RU2161482C2 (pt)
SK (1) SK282308B6 (pt)
WO (1) WO1994028895A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
GB2329583A (en) * 1997-09-25 1999-03-31 Marilyn Rydstrom Use of tea-tree oil for prophylaxis against cystitis
ATE350048T1 (de) 1998-04-16 2007-01-15 Eurovita As Neue synergistische zusammensetzungen, die aromatische verbindungen und in alpinia galanga vorhandene terpenoide enthalten
US6420435B1 (en) 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6733794B1 (en) * 1999-12-17 2004-05-11 Edward L. Ingram Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
DE202009010937U1 (de) 2008-09-04 2010-02-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpene für die Behandlung von Atemwegserkrankungen, insbesondere von bronchopulmonalen Erkrankungen
DE202010007074U1 (de) 2010-05-12 2011-08-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
DE102010022174A1 (de) 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
US8568776B2 (en) * 2011-02-11 2013-10-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
DE202012000910U1 (de) 2012-01-20 2013-01-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) * 2012-03-12 2012-07-12 Lotte Co Ltd 線毛運動活性化剤及びそれを含む飲食品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
JP2524709B2 (ja) * 1985-09-26 1996-08-14 塩野義製薬株式会社 鎮痛消炎作用増強剤
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
JPH0426619A (ja) * 1990-05-18 1992-01-29 Lotte Co Ltd 抗アレルギー剤および抗アレルギー剤を含有する食品添加物
WO1992017064A2 (en) * 1991-04-08 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of protein kinase c function
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US5338758A (en) * 1992-04-03 1994-08-16 Schering Corporation Bicyclic diterpene PAF antagonist compounds
DE4211745A1 (de) * 1992-04-03 1993-10-07 Boerner Gmbh Verwendung von Propolis und/oder seinen Fraktionen
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Also Published As

Publication number Publication date
HU9500714D0 (en) 1995-04-28
CA2140660A1 (en) 1994-12-22
RU2161482C2 (ru) 2001-01-10
WO1994028895A3 (de) 1995-04-06
DE59407336D1 (de) 1999-01-07
BG99499A (bg) 1995-12-29
EP0654994B1 (de) 1998-11-25
AU680663B2 (en) 1997-08-07
BR9405404A (pt) 1999-05-25
AU7000394A (en) 1995-01-03
DK0654994T3 (da) 1999-08-09
EP0654994A1 (de) 1995-05-31
ATE173622T1 (de) 1998-12-15
CZ37095A3 (en) 1995-11-15
US5889049A (en) 1999-03-30
WO1994028895A2 (de) 1994-12-22
CZ285025B6 (cs) 1999-05-12
ES2126123T3 (es) 1999-03-16
RO111989B1 (ro) 1997-04-30
NO950518D0 (no) 1995-02-10
SK282308B6 (sk) 2002-01-07
JPH08500612A (ja) 1996-01-23
PL308539A1 (en) 1995-08-21
NO313814B1 (no) 2002-12-09
HUT69684A (en) 1995-09-28
NO950518L (no) 1995-02-10
SK30395A3 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
BG62474B1 (bg) Приложение на терпенови съединения за забавянеосвобождаването на арахидонова киселина и на възпалителнимедиатори
Juergens et al. Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo
EP1024146B1 (en) Use of a steroid saponin for the treatment of dementia
Juergens et al. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro
EP1696932B1 (en) Use of treprostinil to improve kidney functions
Gw et al. Some effects of adrenal cortical steroids on intermediary metabolism.
US5260335A (en) Pharmaceutical preparations for the treatment of inflammatory diseases
McDougal et al. Biosynthetic and morphological evidence for inhibition of aldosterone production following administration of ACTH to sheep
Freesemann et al. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver
US10124012B2 (en) Method for treatment of hyperglycemia and hyperlipidemia
Leitch Leukotrienes and the lung
DE4319556C2 (de) Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
CN101070338A (zh) 丹参酮ⅱa磺酸钾用于制备预防和治疗心肌缺血缺氧、脑缺血缺氧的药物
US6498145B1 (en) Use of purified SDG as a hypotensive (vasodilator) agent
Dahlgren et al. Effect of indomethacin on local cerebral blood flow in awake, minimally restrained rats
JP2522962B2 (ja) 乾癬治療剤
WO2019232740A1 (zh) 一种用于防治糖尿病的药物组合物及其用途
Garrod The pharmacology of cortisone, cortisol (hydrocortisone) and their new analogues
Mantero 4 Exogenous mineralocorticoid-like disorders
Asenjo-Bueno et al. MO581: Hyperphosphatemia Induces Lung Fibrosis in OLD Mice
Akkuş et al. Cushing syndrome induced by long term use of corticosteroids in the management of atopic dermatitis
Pinto et al. Diazepam administered prior to coronary artery occlusion increases latency to ventricular fibrillation
KR100245670B1 (ko) 종양괴사인자 매개성 피부질환 치료제 조성물
Berti et al. Nimesulide, a Nonsteroidal Anti-Inflammatory Drug, Displays Antianaphylactic and Antihistaminic Activity in Guinea-Pigs
Jaimovich et al. Management of reactive airway disease